| アブストラクト | PURPOSE: To evaluate the cases of corneal graft rejection following SARS-CoV-2 vaccination reported to Centers for Disease Control and Prevention Vaccine Adverse Event Reporting System. METHODS: A descriptive analysis of the demographics, clinical history and presentation was performed. We evaluated the correlation between the vaccines and duration of vaccine-associated graft rejection (VAR) onset following vaccination using a one-way analysis of variance test. A post hoc analysis was performed between VAR onset-interval following vaccination dose and vaccine type. Finally, a 30-day cumulative incidence analysis was performed to assess the risk of VAR in short term following different doses, vaccines and type of corneal transplantation. RESULTS: A total of 55 eyes of 46 patients were diagnosed with VAR following vaccination with BNT162b2 (73.91%) and mRNA-1273 (26.09%). The mean age of the patients was 62.76+/-15.83 years, and 28 (60.87%) were female. The patients diagnosed with VAR had undergone penetrating keratoplasty (61.82%), Descemet membrane endothelial keratoplasty (12.73%), descemet stripping endothelial keratoplasty (18.18%), anterior lamellar keratoplasty (3.64%) and corneal limbal allograft transplantation (1.82%). The mean time for VAR since penetrating and endothelial keratoplasty was 8.42+/-9.23 years and 4.18+/-4.40 years, respectively. 45.65% of the cases of VAR were reported after the second dose of vaccine. The duration of VAR onset was significantly shorter after the second dose compared with the first and booster doses (p=0.0165) and in patients who underwent endothelial keratoplasty compared with penetrating keratoplasty (p=0.041). CONCLUSIONS: This study outlines a possible temporal relationship between corneal graft rejection and SARS-CoV-2 vaccination. An earlier onset of VAR was observed in patients who had a history of endothelial keratoplasty and following the second dose of vaccination. |
|---|
| 組織名 | Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School,;Boston, Massachusetts, USA.;Ophthalmology and Visual Sciences, The University of Adelaide Faculty of Health;and Medical Sciences, Adelaide, South Australia, Australia.;Jules Stein Eye Institute, Department of Ophthalmology, David Geffen School of;Medicine, University of California Los Angeles, Los Angeles, California, USA.;Department of Ophthalmology, Government Medical College and Hospital, Chandigarh,;India.;Scheie Eye Institute, Department of Ophthalmology, University of Pennsylvania;Perelman School of Medicine, Philadelphia, Pennsylvania, USA.;Eye and Ear Insitute, Department of Ophthalmology, University of Pittsburgh;School of Medicine, Pittsburgh, Pennsylvania, USA jhanjiv@upmc.edu. |
|---|
